News & Events

In the news


Naobios and FluGen begin collaboration to optimize manufacturing process for M2SR quadrivalent influenza vaccine

Naobios is announcing today that it has started the process optimization for a quadrivalent version of FluGen’s M2SR influenza vaccine. Naobios previously performed process development and cGMP manufacturing of FluGen’s monovalent M2SR vaccine for a recently completed clinical trial.

Clean Mails – June 2023

Assessing the scale-X(TM) bioreactor’s biomanufacturing capacities on Vero cells

To further extend their biomanufacturing capabilities and cater to Univercells clients' growing needs, Naobios has recently conducted a comprehensive assessment of the performance of Vero cells cultured within the scale-X(TM) bioreactor provided by Univercells Technologies. This assessment aimed to evaluate the compatibility and efficiency of the Vero cell line in this novel bioreactor system for viral-based bioproduction.

Clean Mails – May 2023

New equipment for biomanufacturing

Biomanufacturing is a complex process which requires live material, experienced staff, and modern equipment. In order to generate innovative medicine from cells and viruses – inherently variable material, various tools are used to create a stable biomanufacturing environment ensuring reproducibility. An expert CDMO, Naobios increased its biomanufacturing capacity by implementing and qualifying two new Kuhner incubator shakers and one Sartorius bioreactor for process development and GMP purposes.

Save the date !

Congresses 2023: meet our teams!

Teams at Naobios are traveling the world to attend major conferences and congresses within the biotech sector. As leaders of the biopharma field, our mission and our drive at the Clean Biologics group are to remain both reachable and up-to-date with regards to the latest developments and innovations.

Clean Mails – December 2022

Naobios signs a Research License Agreement with Valneva on EB66® cell line.

Naobios today announces the signature of a Research License Agreement with Valneva to assess the EB66® cell line as cell substrate for the evaluation of alternative bioprocess design and new technologies.

Clean Mails – December 2022

Naobios, your partner in the production of Human Viral Challenge Agents

Naobios today announces its investment in the manufacturing of Human Viral Challenge Agents.

Clean Mails – September 2022

Naobios x GenSensor: a partnership for bioprocess optimization

Naobios and GenSensor, two renowned companies of the biopharma sector, have announced a partnership to further advance bioprocess optimization for clinical lots of viral vaccines and vectors. It will allow for enhanced bioprocesses and optimized scale-up.

Press Release

Naobios delivers FluGen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials

Naobios’ development work and GMP manufacturing of vaccine clinical batches enables FluGen to conduct its 2022 clinical trials in the United States.